COVID-19 infection | The phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.
Dr Reddyâs submits phase 2 safety data of Sputnik V for DCGIâs approval
Dr Reddyâs submits phase 2 safety data of Sputnik V for DCGIâs approval
12 January 2021 | News The phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomised, double-blind, parallel-group, placebo-controlled study in India
Source credit: Shutterstock
Dr Reddy’s Laboratories Ltd has announced that the independent Data and Safety Monitoring Board (DSMB) has reviewed the safety data from the phase 2 clinical trial of the Sputnik V vaccine and recommended the phase 3 recruitment and continue the clinical trial without any modifications.
The phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomised, double-blind, parallel-group, placebo-controlled study in India. The DSMB concluded that no safety concerns were identified and the study has met the primary endpoints of safety. Further, the safety data has been submitted to the Drugs Co
Sputnik V - produced by Russian government-Dr. Reddy's Labs has submitted its phase-2 trial data to Drug Controller General of India (DCGI), ahead of rollout
Hyderabad (Telangana) [India], January 11 (ANI): The Russian made Covid-19 vaccine Sputnik V has met the primary endpoint of safety in the phase-2 clinical trials in India and has been recommended to continue the clinical trial without any modifications, according to an official statement.
Dr Reddy’s Laboratories launches Febuxostat tablets
× Dr Reddy’s Laboratories Ltd has launched Febuxostat Tablets, a therapeutic equivalent generic version of Uloric (Febuxostat) tablets approved by the US Food and Drug Administration (USFDA).
The Uloric brand and generic had US sales of approximately $108 million MAT for the most recent twelve months, ending in October 2020, according to IQVIA Health.
Dr Reddy’s Febuxostat tablets are available in 40 mg and 80 mg strengths in bottle count sizes of 30 tablets.
Gout patients with established cardiovascular (CV) disease treated with Febuxostat had a higher rate of CV death compared to those treated with allopurinol in a CV outcomes study, it warned.